IN RESPONSE: Dr. Swartz correctly states that both qSOFA and the SIRS criteria were designed not to diagnose disease but to predict an outcome (1) (2) (3) . Therefore, use of such criteria by clinicians may alter patient outcomes. Given the retrospective design of many of our included articles, Dr. Swartz implies that clinicians probably routinely used the SIRS criteria but not qSOFA to predict death, because most studies used databases that preceded the publication of the latter. Therefore, patients meeting SIRS criteria may have been more aggressively treated by clinicians and had better outcomes. For this contention to be true, 2 assumptions must hold: that clinicians would rigidly adhere to SIRS screening criteria for treatment initiation while not considering the signs of deterioration outlined in qSOFA (tachypnea, hypotension, and altered mental status) and that aggressive treatment based on SIRS criteria alone would improve outcomes.
To address the former, it is clear that both the SIRS criteria and qSOFA are simply more explicit definitions of principles of existing clinical expertise. During development of the Third International Consensus Definitions for Sepsis and Septic Shock criteria, the investigators used a rigorous expert consensus process based on current understanding of sepsis physiology, systematic literature review, and Delphi consensus (1) . In addition, recent trials and meta-analyses on early, goal-directed therapy for septic shock showed that rigid protocols of care are not superior to usual care; this finding reflects the dynamic and evolving nature of "usual care," which itself has become more aggressive (4) . The future of sepsis management may lie with flexible protocols that allow for individualization of treatment approaches based on patientand disease-specific factors.
If the intended use of the SIRS criteria or qSOFA is to determine strict eligibility for aggressive sepsis treatment protocols, then we agree that these concepts cannot be assessed in isolation. As Dr. Swartz correctly states, such a conclusion would require a randomized, interventional study in which the SIRS criteria, qSOFA, and their subsequent treatment algorithms are compared as holistic sepsis management protocols. Our review had a different purpose and provides a more pragmatic understanding of qSOFA as a clinical concept, summarizing the range of performance at external validation across differing populations and settings. (1) performed several meta-analyses of important outcomes after kidney donation. Among these was an analysis of 4 studies on all-cause mortality among kidney donors, including a Canadian study by Garg and associates (2) that had a median follow-up of 6.5 years, a U.S. study by Segev and coworkers (3) that had a follow-up of 6.3 years, and a Norwegian study from our group (4) that had a median follow-up of 14 years. These 3 studies showed different results.
Garg and Segev and their respective colleagues found significantly decreased mortality among kidney donors; our study found increased all-cause mortality. However, the survival curves in our study only started to separate at more than 10 years of follow-up, indicating that increased mortality after kidney donation may manifest only after long-term follow-up. At a follow-up of less than 10 years, the findings from these 3 studies are not contradictory. No published studies on kidney donors oppose our finding of increased mortality only after more than 10 years of follow-up, because none had adequate control groups and sufficiently long follow-up. As such, we believe that performing a meta-analysis on these 3 studies with different follow-up times does not produce valid results.
We are uncertain whether donors included in the fourth study on all-cause mortality among kidney donors by Berger and colleagues (5) were already included in Segev and coworkers' study.
In the Discussion section of their review, O'Keeffe and colleagues comment on their finding of increased all-cause mortality, stating, "The follow-up duration for assessing chronic kidney disease and mortality outcomes may have been inadequate; most studies reporting those outcomes had an average follow-up between 5 and 10 years." In light of our previous comments, this is at best an understatement. We hope that Garg and associates and Segev and coworkers publish updated results from their study cohorts after longer follow-up, which would provide important information and finally enable comparison of long-term results. IN RESPONSE: Our systematic review and meta-analysis involving 52 studies with more than 100 000 living kidney donors found that there is no evidence of increased risk for adverse psychosocial outcomes, mortality, or major chronic diseases (such as cardiovascular disease or type 2 diabetes) among donor compared with nondonor populations. Living kidney donation is associated with a higher relative risk for end-stage renal disease and preeclampsia, but the absolute risk for these outcomes remains low.
Drs. Mjoen and Holdaas correctly note that the length of follow-up differed among the studies included in our metaanalysis of all-cause mortality. The overall mortality estimate reported in our review reflects the risk for a median follow-up time (that is, the median length of follow-up across the re-ported studies) of approximately 8 years. However, if mortality rates change over time, the overall mortality estimate presented in our review will not appropriately reflect the risk for longer follow-up (such as ≥10 years). We agree with Drs. Mjoen and Holdaas that the relatively short follow-up reported by published studies is a limitation of the available evidence and that studies reporting longer-term outcomes for living kidney donors are needed.
Drs. Mjoen and Holdaas also commented on the possible overlap between the living kidney donor population reported in 2 studies (1, 2). We clarify that Segev and coworkers' study included 80 347 donors older than 18 years registered in the Organ Procurement and Transplantation Network through the United Network for Organ Sharing between 1994 and 2009, whereas Berger and colleagues' study included 219 donors aged 70 to 84 years enrolled in the same registry between 1990 and 2010. Given the partial overlap in the baseline recruitment period between these 2 studies that have used the same living donor registry, their populations may have overlapped. However, because fewer than 4% of donors included in Segev and coworkers' study were older than 60 years at baseline, that the potential overlap would strongly bias the meta-analysis estimate is unlikely. Indeed, there is no meaningful difference in the overall estimate for all-cause mortality with and without inclusion of Berger and colleagues' study in the meta-analysis (risk ratio, 0.60 [95% CI, 0.31 to 1 (1) with interest. My parents were born in the 1920s in Oregon. Into adulthood, I never saw them exercise for the sake of exercise. Being active was all that was required. However, ideas about exercise were changing. Jack LaLanne was on television, then came the publication of Dr. Kenneth Cooper's book Aerobics in 1968; the Presidential Physical Fitness Award, which heralded a new emphasis on physical fitness and testing, was initiated the same year. My parents were not interested.
My father required aortic valve replacement in 1982 for a degenerating bicuspid valve. In the mid-1990s, he received his first stent for coronary disease that later led to bypass and even more stents. Although he liked to play golf, travel, and putter around the house doing chores, he was exceptionally uninterested in additional exercise. He died of cardiac disease in May 2004, having done pretty much what he wanted to do, and not much more, for the last 16 years of his life.
My mother has shunned health care her entire life save for childbirth. Exactly 2 days after her 90th birthday, she fell in her kitchen and sustained a pelvic fracture. She came home 3 weeks later and participated in home physical and occupational therapy but made no additional effort. She began using an exercise bicycle in October 2016 only because I convinced her that she wouldn't be able to garden the next spring. A means to an end. She is still at it and intends to garden this spring.
We all age. We all will get frail. We all will die. Frailty will arrive sooner or later despite all efforts to fend it off. Is the endgame to have everyone live as long they can, or is our goal as health care providers to understand that patients have a right to determine what makes them happy? My father was quite content not exercising, and so was my mother until 18 months ago.
I am surprised at the authors' conclusion that "These findings highlight the feasibility and importance of effective longterm, community-based physical activity programs for frail and nonfrail older adults." Importance? Effective? Their study did not show that exercise affected frailty but that it helped improve the ability to rise from a chair. Pink Floyd might have said, "Frailty researchers, leave them retirees alone!" IN RESPONSE: We thank Dr. Ertle for sharing his personal experience, which gives us the opportunity to highlight some key messages.
First, frailty is not an inevitable part of aging; not all older adults become frail and vulnerable. Frailty is a distinct health state characterized by decreased physiologic reserve and increased vulnerability to stressors (such as falls and illness) that independently increases the risk for poor outcomes, including disability and death (1, 2) . Approximately 25% of persons older than 85 years are frail (3, 4) . It seems that Dr. Ertle's parents were robust and not frail. As health care providers, we all enjoy working with the diverse spectrum of older patients whom we encounter daily, from frail 65-year-olds to robust 95-year-olds. Frailty, rather than age, is likely to explain whether our older patients are at risk for disability and other poor outcomes and should be distinguished from ageassociated changes or diseases.
Second, as Dr. Ertle notes, the LIFE (Lifestyle Interventions and Independence for Elders) study showed that sedentary older persons who were encouraged to become more physically active through the LIFE structured exercise program did not have a lower risk for frailty. However, our findings highlight the beneficial effects of this program on the clinical expression of frailty (for example, improved ability to rise from a chair) and support the benefits of exercise in preventing physical disability even in frail older adults. Preserving mobility is central to maintain independence and a good quality of life (5) .
Finally, we concur with Dr. Ertle that patients have a right to determine what makes them happy and that not all older persons are interested in or are likely to begin or adhere to a structured exercise program. However, we should not overlook that physical activity can help maintain and improve physical health at all ages and helps prevent chronic diseases. Health care providers should encourage sedentary older persons to do at least some varied physical activities (defined as any movement produced by skeletal muscles that results in energy expenditure), such as walking or gardening. Clinicians have a unique opportunity to promote their older patients' participation in physical activity, especially activities they may enjoy. (1) show that myeloproliferative neoplasms (MPNs) with subtypes of polycythemia vera, essential thrombocythemia, and myelofibrosis that result in overproduction of erythrocytes, platelets, or other blood cell traits are associated with a higher risk for arterial and venous thrombosis. This finding is consistent with that from a randomized controlled trial showing that targeting a lower hematocrit level in polycythemia vera via phlebotomy and/or hydroxyurea treatment reduced cardiovascular and thrombotic events (2), although the exact mechanism was unclear. Of note, a recent Mendelian randomization study of 36 blood cell traits in ischemic heart disease (IHD), including hematocrit levels, identified a causal role of lower mean platelet volumes and higher reticulocyte counts and percentagesindicators of erythrocyte turnover and increased hemolysis (3). Taken together, these studies indicate that erythrocytes and hemolysis most likely play a role in IHD, potentially suggesting a genetically validated mechanism that could be targeted to facilitate prevention and treatment of thrombosis and IHD in all patients.
TO THE EDITOR: Hultcrantz and colleagues
Hultcrantz and colleagues also show that men with MPNs are more vulnerable to thrombosis than women. This difference has also been found in hemolysis, thrombosis, and IHD (4). Erythrocytes in men are more vulnerable to hemolysis than those in women, a circumstance possibly mediated by sex hormones (4) . From an evolutionary, biological perspective, growth and reproduction trade off against longevity; that is, investment in reproduction may occur at the expense of longevity, which suggests a role of the endocrine system in chronic diseases (5) . Factors that downregulate the reproductive axis might be expected to prevent chronic diseases. For example, several successful therapies for cardiovascular disease (including statins and some antihypertensives, such as spironolactone) suppress the reproductive axis (5). Sex hormones, which modulate erythrocyte traits and hemolysis,
IN RESPONSE:
We agree that the mechanisms behind thrombosis in MPNs are multifactorial and that further research into their pathophysiology is needed. As Drs. Zhao and Schooling state, the hematocrit level and changes in the leukocyte and platelet counts and their properties likely contribute to the increased risk for thrombosis in patients with MPN and possibly also in the general population (1, 2). We unfortunately were not able to assess hematocrit levels, hemolysis activity, or the level of sex hormones, because laboratory results were not recorded in the registers used in the study. Overall, men did have a higher incidence of thrombosis than women in our study. However, the hazard ratios did not differ between men and women when compared with those of matched control participants, indicating that the increase in rate was similar for men and women with MPNs relative to that in control participants. Moreover, the shared traits for blood indices and such complex conditions as cardiovascular disease reported in a cohort of blood donors by Astle and colleagues (3) would also be interesting to assess in patients with MPNs and would especially be interesting in the setting of the 46/1 haplotype, which has been associated with an increased risk for MPN (4). We agree that both blood indices and genetic traits would be of great value to include in prospective trials to further elucidate the mechanisms of arterial and venous thrombosis in patients with MPNs.
Benefits and Harms of Cranial Electrical Stimulation
TO THE EDITOR: I believe that Shekelle and colleagues' (1) search strategy to identify relevant studies and their review itself was biased. Lande and Gragnani's 5-day insomnia study of service members at the Walter Reed National Military Medical Center was reported as showing no difference between those who received cranial electric stimulation and the sham group (2) . In reality, significant effects were seen with treatment on days 1 and 4 and a trend toward clinical significance was seen on day 5 (P < 0.079). More important, service mem-bers slept an average of 43 minutes more per night with cranial electrotherapy stimulation (2).
Shekelle and colleagues' review also included many studies from 40 years ago that used devices long off the market while omitting research relevant to Alpha-Stim technology (Electromedical Products International). This technology has been included in the Federal Supply Schedule and used by the U.S. Department of Veterans Affairs since 2005-the federal government's definition of scientific evidence is less restrictive than that of Shekelle and colleagues. Even the U.S. Food and Drug Administration uses many forms of valid scientific evidence; it also appropriately considers real-world evidence (3).
When society is desperate for new treatment approaches, conducting a review that purposefully restricts the fair review and exchange of all valid scientific evidence defies common sense. Just as some drugs hold a patent on a chemical compound, Alpha-Stim has a patented waveform. Drugs with different chemical makeups and devices with different treatment variables produce different effects. Generalities on outcomes should be approached with caution.
More than 100 reports have been published on AlphaStim during its 37 years of distribution, most done by independent researchers who have received institutional review board approval without funding by Electromedical Products International. Many of these studies are not listed in predominant pharmaceutical research search engines; however, this does not deem them unscientific-a complete database of these studies is accessible at www.alpha-stim.com/healthcare -professionals/research-and-reports. Furthermore, a review of 24 randomized placebo-controlled trials, 12 open-label trials, and case studies specific to Alpha-Stim has been published (4). It contains 3 functional magnetic resonance imaging and electroencephalography studies and a graphical summary of these, followed by annotated abstracts of all known studies on Alpha-Stim. It also contains outcomes of peer-reviewed published surveys by service members and veterans. The latest study published in February 2018 from MD Anderson Cancer Center (5) reports significant improvement in pain (P = 0.013), anxiety (P < 0.001), depression (P = 0.024), and daytime dysfunction (P = 0.002) and a reduction in sedative medication use (P = 0.006) with this treatment. This study would have been excluded in the limited search criteria of Shekelle and colleagues' review, thereby possibly denying veterans a viable treatment option.
If we are actively seeking nonaddictive, safe, and effective treatments for anxiety, insomnia, depression, and pain, a review on the benefits and harms of a treatment should consider all valid scientific evidence without bias, especially when no safety issues exist. That would be a true review of the benefits and harms of cranial electrical stimulation in 2018. 
Jeff Marksberry, MD, CCRP

IN RESPONSE:
We disagree with Dr. Marksberry that our search strategy and review were biased. We searched multiple electronic databases without language restrictions, ClinicalTrials.gov, previous systematic reviews, the reference lists of included studies, studies cited on manufacturers' Web sites, an 11-page document provided by the makers of AlphaStim entitled "Clinical Evaluation Report" that included many citations of studies using the Alpha-Stim device, and a U.S. Food and Drug Administration executive summary (prepared 10 February 2012) in response to a petition to request a change in classification for cranial electrical stimulators. We restricted eligibility to studies measuring clinical outcomes for patients with our target conditions (chronic painful conditions, depression, anxiety, and insomnia) and that were randomized controlled trials, the least-biased study design for assessing effectiveness of interventions for chronic conditions that can have a fluctuating course and variable natural history. We doubt that including additional study designs in our review would have changed our conclusion. Of note, despite the U.S. Food and Drug Administration's inclusion of observational studies in their review, their conclusion was similar: "[The U.S. Food and Drug Administration] has consistently stated that the effectiveness of [cranial electrical stimulation] has not been established by adequate scientific evidence" (1).
Lande and Gragnani's article (2) states, "The study's primary outcome variables were the time to sleep onset, total time slept, and number of awakenings" and that differences between groups were not statistically significant. No result in Table 2 of their article on change in hours in sleep timeincluding measurements on days 2, 3, 4, and 5 of treatment and 3 and 10 days after treatment-is reported as having a statistically significant difference between the treatment and control groups.
We agree with Dr. Marksberry that additional nonaddictive, safe, and effective treatments for anxiety, insomnia, depression, and pain are needed. We look forward to welldesigned and well-conducted studies of cranial electrical stimulation to evaluate its effectiveness.
